Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clin...

Full description

Bibliographic Details
Main Authors: James H. Tabibian, Jayant A. Talwalkar, Keith D. Lindor
Format: Article
Language:English
Published: Hindawi Limited 2013-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2013/389537
id doaj-240c6e8e9c2345e7bda76abb172229ff
record_format Article
spelling doaj-240c6e8e9c2345e7bda76abb172229ff2020-11-24T22:10:53ZengHindawi LimitedBioMed Research International2314-61332314-61412013-01-01201310.1155/2013/389537389537Role of the Microbiota and Antibiotics in Primary Sclerosing CholangitisJames H. Tabibian0Jayant A. Talwalkar1Keith D. Lindor2Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Sreet SW, Rochester, MN 55905, USADivision of Gastroenterology and Hepatology, Mayo Clinic, 200 First Sreet SW, Rochester, MN 55905, USAExecutive Vice Provost & Dean, College of Health Solutions, Arizona State University, 550 North 3rd Street, Phoenix, AZ 85004, USAPrimary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clinical evidence implicate the microbiota in the etiopathogenesis of PSC. Here we provide a concise review of these data which, taken together, support further investigation of the role of the microbiota and antibiotics in PSC as potential avenues toward elucidating safe and effective pharmacotherapy for patients afflicted by this illness.http://dx.doi.org/10.1155/2013/389537
collection DOAJ
language English
format Article
sources DOAJ
author James H. Tabibian
Jayant A. Talwalkar
Keith D. Lindor
spellingShingle James H. Tabibian
Jayant A. Talwalkar
Keith D. Lindor
Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
BioMed Research International
author_facet James H. Tabibian
Jayant A. Talwalkar
Keith D. Lindor
author_sort James H. Tabibian
title Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
title_short Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
title_full Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
title_fullStr Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
title_full_unstemmed Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
title_sort role of the microbiota and antibiotics in primary sclerosing cholangitis
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2013-01-01
description Primary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clinical evidence implicate the microbiota in the etiopathogenesis of PSC. Here we provide a concise review of these data which, taken together, support further investigation of the role of the microbiota and antibiotics in PSC as potential avenues toward elucidating safe and effective pharmacotherapy for patients afflicted by this illness.
url http://dx.doi.org/10.1155/2013/389537
work_keys_str_mv AT jameshtabibian roleofthemicrobiotaandantibioticsinprimarysclerosingcholangitis
AT jayantatalwalkar roleofthemicrobiotaandantibioticsinprimarysclerosingcholangitis
AT keithdlindor roleofthemicrobiotaandantibioticsinprimarysclerosingcholangitis
_version_ 1725806501350604800